FDA Reverses Course on Moderna mRNA Flu Shot After Political Dispute

The U.S. Food and Drug Administration (FDA) has officially agreed to review Moderna’s mRNA-based influenza vaccine, marking a dramatic pivot in a regulatory saga that has gripped the biotech industry. This decision ends a period of intense public friction between the Massachusetts-based pharmaceutical giant and federal regulators. The controversy peaked when reports surfaced that the Trump administration’s vaccine chief had personally intervened to reject the filing, reportedly overstepping the recommendations of the agency’s career scientific staff. This reversal not only clears a path for Moderna’s most critical non-COVID product but also raises significant questions about the stability of the regulatory environment under the current administration.

For Moderna, the stakes could not be higher. As revenues from its COVID-19 vaccines continue to normalize, the company has pivoted its entire growth strategy toward a broader respiratory portfolio, with the flu shot (mRNA-1010) serving as the cornerstone. The initial rejection was viewed by many analysts as a catastrophic blow to the company’s platform thesis—the idea that mRNA technology could be rapidly adapted to various pathogens with predictable regulatory success. By securing this review, Moderna regains its footing in the race to modernize the $7 billion global influenza market, which is currently dominated by traditional egg-based and cell-based vaccines from competitors like Sanofi and CSL Seqirus.

“

By securing this review, Moderna regains its footing in the race to modernize the $7 billion global influenza market, which is currently dominated by traditional egg-based and cell-based vaccines from competitors like Sanofi and CSL Seqirus.

The U-turn by the FDA is particularly noteworthy because it highlights a rare public fracture within the agency. Sources indicate that the initial refusal to file (RTF) was not based on a lack of clinical efficacy—Moderna has previously shared Phase 3 data showing strong immunogenicity against all four A and B strains of the flu—but rather on procedural or administrative disagreements championed by political appointees. The resolution of this dispute suggests either a compromise on data presentation or a strategic retreat by the administration in the face of scientific and industry pushback. This incident will likely serve as a case study for how biotech firms navigate a more volatile, politically charged FDA.

The technical implications for the mRNA platform are profound. Unlike traditional flu vaccines, which require months of manufacturing in chicken eggs or mammalian cells, mRNA vaccines can be synthesized in weeks. This speed allows for a closer-to-season strain selection, potentially increasing the vaccine's match with circulating viruses and improving overall efficacy. However, mRNA vaccines have historically shown higher rates of systemic side effects, such as fever and fatigue, compared to traditional flu vaccines. Moderna will need to convince the agency that the superior efficacy seen in some trials outweighs these reactogenicity concerns.